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Drug survival of second biological DMARD
therapy in patients with rheumatoid
arthritis: a retrospective non-interventional
cohort analysis
Thomas Wilke1*, Sabrina Mueller1,2, Sze Chim Lee1, Istvan Majer3 and Marieke Heisen3
Abstract
Background: Since persistence to first biological disease modifying anti-rheumatic drugs (bDMARDs) is far from
ideal in rheumatoid arthritis (RA) patients, many do receive a second and/or third bDMARD treatment. However,
little is known about treatment persistence of the second-line bDMARD and it is specifically unknown whether the
mode of action of such a treatment is associated with different persistence rates. We aimed to assess
discontinuation-, re-initiation- or continuation-rates of a 2nd bDMARD therapy as well as switching-rates to a third
biological DMARD (3rd bDMARD) therapy in RA patients.
Method: Analysis was based on German claims data (2010–2013). Patients were included if they had received at
least one prescription for an anti-TNF and at least one follow-up prescription of a 2nd bDMARD different from the
first anti-TNF. Patient follow-up started on the date of the first prescription for the 2nd bDMARD and lasted for
12 months or until a patient’s death.
Results: 2667 RA patients received at least one anti-TNF prescription. Of these, 451 patients received a second
bDMARD (340 anti-TNF, mean age 52.6 years; 111 non-anti-TNF, mean age 55.9 years).
During the follow-up, 28.8% vs. 11.7% of the 2nd anti-TNF vs. non-anti-TNF patients (p < 0.001) switched to a 3rd
bDMARD; 14.1% vs. 19.8% (p = 0.179) discontinued without re-start; 3.8% vs.1.8% (p = 0.387) re-started and 53.5 vs.
66.7% (p < 0.050) continued therapy. Patients in the non-anti-TNF group demonstrated longer drug survival
(295 days) than patients in the anti-TNF group (264 days; p = 0.016).
Independent variables associated with earlier discontinuation (including re-start) or switch were prescription of an
anti-TNF as 2nd bDMARD (HR = 1.512) and a higher comorbidity level (CCI, HR = 1.112), whereas previous painkiller
medication (HR = 0.629) was associated with later discontinuation or switch.
Conclusions: Only 56.8% of RA patients continued 2nd bDMARD treatment after 12 months; 60% if re-start was
included. Non-anti-TNF patients had a higher probability of continuing 2nd bDMARD therapy.
Keywords: Rheumatoid arthritis, bDMARD therapy, Anti-TNF, Continuation of bDMARD therapy, Switch of bDMARD
therapy
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Background
Rheumatoid arthritis (RA) is a chronic systemic auto-
immune inflammatory disease with a prevalence of ≥1%
in western countries [1, 2]. Poorly controlled RA results
in severe progressive joint damage, functional disability,
morbidity, poor health-related quality of life, and higher
mortality than in the general population [3, 4].
Current treatment guidelines recommend methotrex-
ate (MTX), a synthetic disease-modifying anti-rheumatic
drug (sDMARD), in combination with glucocorticoids to
be administered for most newly diagnosed RA patients
[5, 6]. If MTX therapy fails to improve symptoms or fails
to reach the treatment target, it is recommended to
switch to another sDMARD (e.g., sulfasalazine, lefluno-
mide, hydroxychloroquine) or to add a biological
DMARD (bDMARD) to MTX therapy. Based on the
mechanism of action, two broad classes of bDMARDs
are distinguished: anti-TNFs (e.g., Infliximab, Etanercept,
Adalimumab, Golumumab, Certolizumab) and non-anti
TNFs (e.g., Abatacept, Anakinra, Tocilizumab, Rituxi-
mab) [7–9].
While most patients initially respond to first-line
bDMARD, several studies reported that up to two thirds
of the patients discontinue such a therapy after
12 months, mainly due to loss of efficacy and/or intoler-
able side effects [10–14]. A previous study showed that a
substantial proportion of patients receives further lines
of biologic treatment after such a discontinuation [15].
Since discontinuation and subsequent switching of
treatments is mostly associated with either a treatment
failure or serious adverse events, it has been frequently
argued that long-term continuation of a particular
bDMARD therapy (i.e., long drug survival) is a
favourable outcome from both a clinical and economic
perspective [10, 11, 16–22]. However, it is a matter of
debate whether after a first anti-TNF therapy, treatment
with a second-line anti-TNF or treatment with a non-
anti-TNF biological is a strategy that maximizes drug
survival of a second bDMARD therapy.
Previous studies assessing and comparing 2nd-line
anti-TNF and non-anti TNF strategies in terms of drug
survival are rare. So far, it has been found that less than
50% of the RA patients still continue a second-line
bDMARD therapy after 1 year [14, 23–25]. Our study
adds further evidence to this literature using a larger
sample than most previous studies did.
In this analysis, we aimed to assess the drug sur-
vival of a second bDMARD therapy in RA patients
hypothesizing that there is a difference in drug sur-
vival between a second anti-TNF versus non-anti-TNF
therapy. By describing drug survival, we aimed to dis-
tinguish a switch to a 3rd-line bDMARD therapy
from restart, discontinuation and continuation of a
2nd-line bDMARD therapy.
Methods
A retrospective non-interventional cohort analysis was
performed using anonymized medical insurance claims
data provided by the AOK Plus, a German statutory
health insurance fund with 3 million insured persons.
German claims data have been found to be a reliable
data source for health care analyses, especially those ad-
dressing outpatient drug treatment of patients [26–28].
Our analysis was done for the calendar years 2010–
2013. RA patients were included if they were ≥18 years
old, had ≥1 outpatient visit with an RA-related ICD-10
diagnosis code (M05 or M06, excluding M06.1: adult-
onset still disease) and/or ≥1 hospital admission with an
RA-related ICD-10 diagnosis code prior to the first pre-
scription of an anti-TNF. Moreover, included patients
should have had a prescription of a first anti-TNF
treatment and, additionally, of a second bDMARD (ei-
ther anti-TNF or non-anti TNF). Date of first prescrip-
tion of the second bDMARD was defined as index date.
Patients were selected for inclusion only if they were en-
rolled in the health insurance database at 01/01/2010
and could be followed for ≥12 months for drug survival
after index date. Patients who died during this 12-month
follow-up were included, however patients who received
a Rituximab treatment as 2nd-line bDMARD treatment
were described but excluded from the analysis because
per label Rituximab treatment should be discontinued
or delayed until disease activity returns, and informa-
tion about disease activity was not available in our
database [29].
In agreement with the study objective, the date of the
first prescription of the second bDMARD was defined as
the index date. For the purpose of the analysis, it was as-
sumed that a patient discontinued a second bDMARD
therapy if there was no documented prescription for
≥90 days (sensitivity analysis: ≥ 180 days) after the esti-
mated end date of the drug supply. Based on the pre-
scribed package size the duration of drug supply was
estimated in terms of days according to the defined daily
dose (DDD) as determined by the World Health
Organization for each bDMARD (Additional file 1). If
after an observed treatment gap of ≥90 days a patient re-
ceived a new prescription of the same second bDMARD
the patient was classified as a re-starting patient. Alter-
natively, a patient who received a new prescription for a
third bDMARD was labeled as a switching patient. All
remaining patients were classified 2nd-line bDMARD
treatment continuers.
Statistical analysis
Patient characteristics were obtained for and compared
between the anti-TNF and non-anti-TNF groups.
Characteristics measured as continuous variables were
compared applying Mann-Whitney U test whereas
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categorical variables were compared using Fisher’s exact
test. Patient populations were considered statistically dif-
ferent along a particular characteristic if the P value was
lower than 0.05.
Total discontinuation rates were reported for the 12-
month follow-up period for the anti-TNF and non-anti-
TNF groups, and were reported separately for patients
who restarted the second bDMARD therapy, who
switched to a third bDMARD therapy, and who discon-
tinued the second bDMARD without receiving any doc-
umented further biologic treatment. Drug survival of the
second bDMARD treatment was estimated using the
Kaplan-Meier method and compared between patients
who received an anti-TNF versus a non-anti-TNF
second bDMARD by means of log-rank tests. Both
switching and discontinuation of 2nd-line bDMARD
therapy were considered as an event indicating no drug
survival. As restarting of a therapy follows on discon-
tinuation of the same therapy, this was not considered a
separate event on top of discontinuation.
To account for differences in patient characteristics
between RA patients who received anti-TNFs versus
non-anti TNFs as 2nd-line bDMARD, we estimated the
hazard ratio (HR) of treatment discontinuation (non-
anti-TNF versus anti-TNF) by multivariable Cox propor-
tional hazards models. Again, both switching and
discontinuation of 2nd-line bDMARD therapy was con-
sidered as an event. The following risk factors were
initially included in the model and covariates were se-
lected via backward elimination (p > 0.100): age, gender,
Charlson Comorbidity Index (CCI) without age as factor,
prescribed medications in the 6 months before 2nd-line
bDMARD initiation (12 different ATC groups),
concomitant sDMARD therapy, concomitant and previ-
ous painkiller prescriptions (anesthetics, analgesics, non-
steroidal anti-inflammatory and antirheumatic agents
and celecoxib with ATC codes: N01*, N02*, M01A*,
L01XX33), concomitant corticosteroid prescriptions
(glucocorticoids for systemic use and glucocorticoids
combinations with ATC codes: H02AB*, H02BX*), and
adverse events during first bDMARD therapy (see Add-
itional file 2 for further details). Factors reaching a
p < 0.05 were interpreted as statistically significant. All
reported p-values were two-sided, and 95% CIs were cal-
culated for Hazard Ratios (HRs). Descriptive evaluations
were performed with Microsoft SQL Server 2013 and
Microsoft Excel 2013. All other statistical analyses were
performed with SPSS 17.0/STATA 13.1.
Results
Patient sample
We identified 2667 RA patients with a first observable
anti-TNF prescription during 01/01/2010–31/12/2012
(Additional file 3). Among these, 495 patients received
at least one prescription for a 2nd bDMARD (mean age:
53.9 years, 76.8% female, CCI 2.12, exposure time:
180,419 days; 364.5 days per patient); 340 had received
an anti-TNF (116 Adalimumab, 42 Certolizumab, 120
Etanercept, 46 Golimumab, 16 Infliximab; mean age:
52.9 years, 77.4% female, CCI 2.11, exposure time:
123,844 days; 364.2 days per patient), and 155 had re-
ceived a non-anti-TNF (40 Abatacept, 3 Anakinra, 68
Tocilizumab, 44 Rituximab, mean age: 56.2 years, 75.5%
female, CCI 2.14, exposure time: 56,575 days; 365.0 days
per patient). Because Rituximab patients were excluded
from the study sample, the final dataset consisted of 451
RA patients (111 non-anti-TNF). The patients who re-
ceived a 2nd anti-TNF were younger than the patients
who received a 2nd non-anti-TNF (p = 0.055). Further-
more, patients who received a non-anti TNF also
received corticosteroids both before and after index date
with a higher probability. No significant differences be-
tween the 2nd anti-TNF and non-anti TNF groups could
be observed for gender, CCI, duration of first-line anti-
TNF treatment, and other pre-/post-index medication
like sDMARDs, or painkillers/NSARs (Table 1).
Assessment of 2nd bDMARD drug survival
Table 2 presents the proportion of patients who
switched, discontinued (with and without later re-start)
or remained on second bDMARD therapy during the
12-month follow-up period. In the full population, the
switch, discontinuation, and continuation rates were es-
timated to be 24.6% (95% CI: 20.8–28.8), 18.8% (95% CI:
15.5–22.7), and 56.8% (95% CI: 52.1–61.3), respectively.
Treatment continuation rates were significantly lower in
the anti-TNF group (53.5%, 95% CI: 48.2–58.8) than in
the non-anti-TNF group (66.7%, 95% CI: 57.3–74.9).
This was mainly explained by the switch rates, which
were significantly higher in the anti-TNF group than in
the non-anti-TNF group, 28.8% (95% CI: 24.2–33.9)
versus 11.7% (95% CI: 6.9–19.2) (p < 0.001), respectively.
The 12-month discontinuation rate was somewhat lower
in the anti-TNF group (17.9%, 95% CI: 14.2–22.4) than
in the non-anti-TNF group (21.6%, 95% CI: 14.9–30.3),
however, the difference was not statistically significant
(p = 0.403).
In the sensitivity analysis applying a discontinuation
threshold of ≥180 days, 12-month continuation rates for
the overall sample were higher than in the main analysis
(60.5% instead of 56.7%). Nevertheless, the proportion of
patients who continued therapy was still higher in the
non-anti TNF group (68.5%, 95% CI: 59.2–76.5) com-
pared to the anti-TNF group (57.9%, 95% CI: 52.6–63.1).
Figure 1 depicts second bDMARD drug survival rates
for the anti-TNF and non-anti-TNF populations for the
first year after initiation of a second bDMARD therapy
as KM curves. Patients belonging to the non-anti TNF
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group had a greater chance to continue their second
bDMARD therapy than patients belonging to the anti-
TNF group. This holds true for the entire follow-up
period; LogRank test (p = 0.016) showed this difference
was statistical significant. Estimated mean drug survival
time for the first year after initiation of a second
bDMARD was 294.7 days (95% CI: 274.1–315.3 days) in
the anti-TNF group and 263.8 days (95% CI: 250.6–
277.2 days) in the non-anti-TNF group.
Factors associated with 2nd bDMARD drug survival
In the multivariable Cox regression analysis, several pa-
tient and treatment characteristics were associated with
the time to switch or discontinuation of the 2nd
bDMARD therapy (Fig. 2). Patients who were more co-
morbid as measured by the CCI had a higher risk of dis-
continuing the 2nd bDMARD therapy or switching to a
3rd bDMARD therapy (HR = 1.112; 95% CI: 1.015–
1.219, HR associated with CCI score points). In contrast,
patients who had received at least one prescription for a
painkiller in the 6 preceding months before index date
had a lower risk of discontinuing or switching therapy
(HR = 0.629; 95% CI: 0.462–0.856). Age and gender were
not significantly associated with the probability of
switching or discontinuing 2nd bDMARD treatment. Fi-
nally, patients who started a 2nd bDMARD therapy with
an anti-TNF had a higher risk of a switch or discontinu-
ation of therapy than patients who started with a non-
anti-TNF (HR = 1.512; 95% CI: 1.048–2.182).
Discussion
Study objectives and main results
Using a German claims dataset, we aimed to assess the
level of drug survival in RA patients who started a 2nd
bDMARD therapy after discontinuation of a 1st anti-
TNF therapy, and to compare drug survival between pa-
tients who received an anti-TNF and those who received
a non-anti-TNF as a 2nd bDMARD.
We reported that a substantial number of RA patients
discontinued or switched their 2nd bDMARD therapy
within 12 months. Overall, only 56.8% of the patients
continued their 2nd bDMARD therapy during a 12-
month follow-up. Among those not continuing the 2nd
bDMARD therapy, 56.6% switched to a 3rd bDMARD
therapy, 35.7% discontinued therapy, and the remaining
7.7% re-started therapy after discontinuation. This per-
centage of re-starters may be related to the relatively
short follow-up period of our study.
This study is one of the first studies analyzing drug
survival of a 2nd bDMARD therapy in RA patients.
Moreover, it is the first analysis covering Germany in
this respect. A specific characteristic of our study is that
Fig. 1 12-month drug survival of 2nd bDMARD therapy in RA patients. Shows 12-month drug survival of RA patients having initiated a 2nd
bDMARD therapy. Patients died during the observation period were censored. Differences between patients having received an anti-TNF versus
those having received a non-anti-TNF were analysed using Log-Rank tests
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it reported the percentage of patients who switched, dis-
continued (with and without re-start), or continued ther-
apy separately. This allows a better understanding and
interpretation of drug survival observed in clinical prac-
tice settings. Moreover, because we performed analyses
using claims data instead of prospective or registry data,
the selection bias of our study can be considered to be
minimal.
We acknowledge that discontinuation of a bDMARD
therapy or switching to another bDMARD agent may
not directly imply therapy failure or serious adverse
events. Due to the nature of the dataset, determination
of disease activity and identification of any causes of ad-
verse events was not possible, and thus we were not able
to determine the specific reasons for therapy discontinu-
ation or switches of therapy. However, it is known from
existing literature that approximately 50% of observed
bDMARD therapy switches/discontinuations are due to
lack of disease remission under this therapy, whereas the
remaining 50% are due to serious side effects [18, 20, 30,
31]. Thus, we assumed that our observed discontinu-
ation and switch rates are a reliable proxy to describe
the effectiveness and safety of different 2nd bDMARD
therapies in RA.
Comparison of results with existing publications
Our reported 12-month 2nd bDMARD discontinuation
rates of between 53.5% (anti-TNF) and 66.7% (non-anti-
TNF) are in line with existing literature. However, the
majority of past studies were based on US data and
almost exclusively covered 1st bDMARD therapy in RA
patients. These studies reported 1st bDMARD 12-month
therapy continuation rates of 62.2–68.9% [12], 42–56%
[10, 11], 24–59% [13], and 48–51% [14], and the
differences in the reported rates could be mainly due to
different study designs, definitions of therapy discon-
tinuation and patient sample characteristics. In Europe,
an Italian analysis reported a likelihood of continuing
1st anti-TNF therapy of 78.8% after 12 months, 65.2%
after 24 months, and 52.9% after 36 months, with a risk
of dropout similar for inefficacy and adverse events as
discontinuation causes [21]. A Greek analysis reported
5-year 1st bDMARD continuation rates of 31–49% [32].
In our study, we initially included all RA patients with at
least one anti-TNF prescription to further identify pa-
tients with a second bDMARD. Of all 2667 anti-TNF pa-
tients, only 495 patients (18.5%) received a second
bDMARD. This might indicate a good efficacy/safety of
a first anti-TNF therapy. However, in line with our
methodology, we did not define any index date or mini-
mum follow-up period for the first anti-TNF therapy.
Moreover, patients who discontinued a first anti-TNF
therapy but did not start a second bDMARD therapy
were not specifically identified. So, based on our
numbers, no reliable assessment of first anti-TNF
persistence is possible.
Much less is known about drug survival of 2nd
bDMARD treatment in RA patients. A Spanish analysis
reported DAS-28-based EULAR [33] response levels to
1st anti-TNF of 42% (good) compared to 20% for 2nd
Fig. 2 Predictors of 2nd bDMARD drug discontinuation. Estimation was done using multivariable Cox regression analysis based on a backward
inclusion methodology (all variables with p < 0.100 were included). The model was controlled for age, gender and previous prescribed
medications (differentiated by 12 different ATC main groups). Excluded variables were: concomitant DMARD therapy, concomitant painkiller
medication, concomitant corticosteroid medication, adverse events before index date as defined in Additional file 2. Results are shown as 95%-CIs
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anti-TNF therapy, which could indicate a lower continu-
ation rate of a 2nd anti-TNF therapy compared to a 1st
anti-TNF therapy [23]. Another US publication reported
30–36 weeks 2nd bDMARD continuation rates of
46–56% [14].
In our study, neither sex nor age was associated with
2nd bDMARD drug survival, which was also shown in a
Canadian analysis [24], whereas a Spanish single-centre
analysis found age to be associated with therapy
continuation [25]. In our analysis, previous painkiller
medication was associated with a lower probability of
discontinuing 2nd bDMARD treatment. To our know-
ledge, no such relationship has been found in previous
studies. If painkiller medications are associated with
severity of RA symptoms, this could mean that patients
experiencing more or more severe RA symptoms have a
higher probability of continuing their 2nd bDMARD
treatment.
Additionally, in our analysis a higher comorbidity sta-
tus and a 2nd anti-TNF treatment compared to a non-
anti-TNF therapy were associated with an earlier 2nd
bDMARD switch or discontinuation. This was also
shown by most of the previous studies [10, 19, 30].
Limitations
We acknowledge several limitations of our analyses. Due
to the nature of our dataset, we could only observe a
12 months follow-up period after the start of 2nd
bDMARD therapy. We also assumed that the first
observed anti-TNF therapy in a patient was equivalent
to the first-line bDMARD therapy this patient received.
It is unknown whether some of the patients had already
received other bDMARDs in previous unobserved
periods, which could mean that we interpreted a
bDMARD therapy to be a 2nd bDMARD therapy also
when it was a therapy beyond the second line.
We defined discontinuation as a treatment gap of at
least 90 days. Because most of bDMARD package sizes
cover a DDD-based drug supply of 30–90 days, we iden-
tified the first therapy discontinuers 120–180 days after
therapy start. While the threshold of 90 days is widely
used in the literature [13], it has so far hardly been clin-
ically validated. We dealt with this weakness by addition-
ally using a threshold of at least 180 days. Our results
show, as expected, that reported discontinuation rates
decreased on the basis of this threshold, albeit only by a
small percentage (14.9% discontinuation rate based on
180-day gap versus 18.8% based on 90-day gap).
In our analysis, which addressed outpatient bDMARD
drug treatment only, we assumed that the start date of a
therapy was equal to the date of filling a bDMARD pre-
scription. If the application of the drug was done some
days later than that, we assumed an earlier therapy start
date than actually implemented. Moreover, stop date of
a therapy was calculated based on the provided drug
supply of each prescription. If packages were not used
completely, we nevertheless assumed that the therapy
was continued until the provided package was
completely used. In addition to that, primary non-
adherence (patient received prescription, but did not fill
it) was not included into our analysis because of the
nature of the dataset.
Additionally, we had only limited data with regard to
potential factors associated with 2nd bDMARD discon-
tinuation. Detailed data about RA disease severity and
disease characteristics which may predict treatment
outcomes and, consequently, treatment continuation
were not available. So, due to unobserved patient and
treatment characteristics, the results of the comparison
of drug survival between anti-TNF and non-anti-TNF
agents may be biased.
Conclusions
Conclusions and implications for practice
Over 50% of German RA patients discontinue their 2nd
bDMARD treatment within 12 months after initiation.
Patients on non-anti TNF biological DMARDs seem to
have a higher drug survival and seem less likely to
switch their therapy. We presume that, after an anti-
TNF failure, this finding is related to the different mode
of action of non-anti TNFs.
Key messages
At least 50% of RA patients discontinue the 2nd
bDMARD treatment within 12 months after initiation.
Patients on non-anti TNF bDMARDs as 2nd
bDMARD therapy have a lower probability to discon-
tinue their treatment.
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